Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG Strong (also known as PG Strong Drop) is a medical cannabis flower product distributed by DEMECAN in Germany, sourced from cultivation partners in Canada. The "PG" prefix refers to Preferred Gardens, a US-based legacy cannabis cultivator that partners with DEMECAN to bring premium genetics to the European medical market. PG Strong is available in specific cultivars, such as 'Gas Face' (a Sativa-dominant hybrid) and 'Purple Octane' (an Indica-dominant hybrid), typically featuring high tetrahydrocannabinol (THC) concentrations of approximately 24.5% to 27% and low cannabidiol (CBD) levels (<1%). It is prescribed for patients in Germany to manage conditions such as chronic pain, anxiety, sleep disorders, and depression, exerting its therapeutic effects primarily through the activation of central and peripheral cannabinoid receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PG Strong.